↓ Skip to main content

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Overview of attention for article published in Blood, June 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
4 X users
patent
19 patents

Citations

dimensions_citation
184 Dimensions

Readers on

mendeley
91 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Published in
Blood, June 2011
DOI 10.1182/blood-2011-04-348896
Pubmed ID
Authors

Martha Q. Lacy, Jacob B. Allred, Morie A. Gertz, Suzanne R. Hayman, Kristen Detweiler Short, Francis Buadi, Angela Dispenzieri, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, David Dingli, Steven Zeldenrust, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, A. Keith Stewart, Kristina Laumann, Sumithra J. Mandrekar, Craig Reeder, S. Vincent Rajkumar, Joseph R. Mikhael

Abstract

Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was given orally 2 or 4 mg daily with dexamethasone 40 mg weekly. Thirty-five patients were enrolled in each cohort. Confirmed responses in the 2-mg cohort consisted of very good partial response (VGPR) in 5 (14%), partial response (PR) in 4 (11%), minor response (MR) in 8 (23%) for an overall response rate of 49%. In the 4-mg cohort, confirmed responses consisted of complete response (CR) in 1 (3%), VGPR in 3 (9%), PR in 6 (17%), MR in 5 (14%) for an overall response rate of 43%. Overall survival at 6 months is 78% and 67% in the 2- and 4-mg cohort, respectively. Myelosuppression was the most common toxicity. This nonrandomized data suggests no advantage for 4 mg over the 2 mg daily. Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
United States 1 1%
Unknown 88 97%

Demographic breakdown

Readers by professional status Count As %
Other 22 24%
Researcher 16 18%
Student > Bachelor 7 8%
Student > Master 5 5%
Student > Ph. D. Student 4 4%
Other 15 16%
Unknown 22 24%
Readers by discipline Count As %
Medicine and Dentistry 35 38%
Agricultural and Biological Sciences 9 10%
Pharmacology, Toxicology and Pharmaceutical Science 6 7%
Economics, Econometrics and Finance 3 3%
Biochemistry, Genetics and Molecular Biology 2 2%
Other 9 10%
Unknown 27 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2024.
All research outputs
#4,300,739
of 25,373,627 outputs
Outputs from Blood
#6,436
of 33,239 outputs
Outputs of similar age
#22,039
of 126,622 outputs
Outputs of similar age from Blood
#59
of 277 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,239 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 126,622 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 277 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.